论文部分内容阅读
目的观察长春西汀联合醒脑静治疗急性脑梗死的临床疗效。方法将急性脑梗死患者60例随机分为对照组和治疗组,每组30例,对照组给予注射用血栓通治疗,治疗组给予长春西汀联合醒脑静静脉滴注治疗,两组疗程均为14 d。比较两组治疗前后神经功能缺损评分(National Institutes of Health Stroke Scale,NIHSS)改善状况及临床疗效。结果治疗组治疗前后NIHSS评分分别为12.48±3.48和6.14±3.07,对照组分别为12.72±4.03和8.32±3.61,治疗组改善状况优于对照组,差异有统计学意义(P<0.05);治疗组总有效率为86.7%,优于对照组的63.3%,其差异有统计学意义(P<0.05)。结论长春西汀联合醒脑静治疗急性脑梗死安全有效。
Objective To observe the clinical efficacy of vinpocetine combined with xingnaojing in treating acute cerebral infarction. Methods Sixty patients with acute cerebral infarction were randomly divided into control group and treatment group, 30 cases in each group. The control group was treated with Xueshuantong Injection. The treatment group was given Vinpocetine combined with Xingnaojing intravenous infusion. For 14 days. The improvement and clinical efficacy of the National Institutes of Health Stroke Scale (NIHSS) before and after treatment were compared between the two groups. Results The NIHSS scores of the treatment group before and after treatment were 12.48 ± 3.48 and 6.14 ± 3.07, respectively, while those in the control group were 12.72 ± 4.03 and 8.32 ± 3.61, respectively. The improvement in the treatment group was better than that in the control group (P <0.05) The total effective rate was 86.7%, better than 63.3% of the control group, the difference was statistically significant (P <0.05). Conclusion Vinpocetine combined with Xingnaojing in the treatment of acute cerebral infarction is safe and effective.